Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-Outcomes of a randomized trial

Drug and Alcohol Dependence

Volumn 133, Issue 2, 2013, Pages 376-382

  Otiashvili, David ^a,f   Piralishvili, Gvantsa ^b   Sikharulidze, Zura ^c   Kamkamidze, George ^d   Poole, Sabrina ^e   Woody, George E ^e  

^a Addiction Research Center   (Georgia)

^b Center for Mental Health and the Prevention of Addiction   (Georgia)

^c Socio economic and Cultural Issues   (Georgia)

^d Maternal and Child Care Union   (Georgia)

^e TREATMENT RESEARCH INSTITUTE   (United States)

^f CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Buprenorphine abuse; Republic of Georgia; Treatment

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DESOMORPHINE; DIAMORPHINE; METHADONE; OPIATE; OPIATE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DRUG ABUSE; DRUG EFFICACY; DRUG FATALITY; FEMALE; FOLLOW UP; GEORGIA (REPUBLIC); HELP SEEKING BEHAVIOR; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NARCOTIC DEPENDENCE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT BATTERY; RISK REDUCTION; SCORING SYSTEM; SELF REPORT; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINALYSIS;

HEPATITIS C VIRUS;

BUPRENORPHINE ABUSE; REPUBLIC OF GEORGIA; TREATMENT;

ADULT; BUPRENORPHINE; FEMALE; GEORGIA (REPUBLIC); HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; METHADONE; NARCOTICS; NEEDLE SHARING; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RISK-TAKING; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 84887015331     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.06.024     Document Type: Article

References (53)

1. Aalto M., Visapaa J.-P., Halme J.T., Fabritius C., Salaspuro M. Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients. Nord. J. Psychiatry 2011, 65:238-243.
2. Ahmadi J., Ahmadi K., Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur. J. Clin. Invest. 2003, 33:824-829.
3. Ahmadi M., Maany I., Ahmadi J. Treatment of intravenous buprenorphine dependence. A randomized open clinical trial. Ger. J. Psychiatry 2003, 6:23-29.
4. Aitken C.K., Higgs P.G., Hellard M.E. Buprenorphine injection in Melbourne, Australia-an update. Drug Alcohol Rev. 2008, 27:197-199.
5. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007, 88:75-78.
6. Booth R.E., Lehman W.E., Dvoryak S., Brewster J.T., Sinitsyna L. Interventions with injection drug users in Ukraine. Addiction 2009, 104:1864-1873.
7. Booth R.E., Lehman W.E., Kwiatkowski C.F., Brewster J.T., Sinitsyna L., Dvoryak S. Stimulant injectors in Ukraine: the next wave of the epidemic?. AIDS Behav. 2008, 12:652-661.
8. Bruce R.D., Govindasamy S., Sylla L., Kamarulzaman A., Altice F.L. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am. J. Drug Alcohol Abuse 2009, 35:68-72.
9. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., Woody G.E. Buprenorphine use: the international experience. Clin. Infect. Dis. 2006, 43(Suppl. 4):S197-S215.
10. Chikovani I., Bozicevic I., Goguadze K., Rukhadze N., Gotsadze G. Unsafe injection and sexual risk behavior among injecting drug users in Georgia. J. Urban Health 2011, 88:736-748.
11. Chua S.M., Lee T.S. Abuse of prescription buprenorphine, regulatory controls and the role of the primary physician. Ann. Acad. Med. Singapore 2006, 35:492-495.
12. Cicero T.J., Surratt H.L., Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J. Opioid Manag. 2007, 3:302-308.
13. Clark H.W. The State of Buprenorphine Treatment. Buprenorphine in the Treatment of Opioid Addiction: Reassessment 2010 2010, Retrieved from http://buprenorphine.samhsa.gov/bwns/2010_presentations_pdf/01_Clark_508.pdf (20.08.12).
14. Comer S.D., Collins E.D. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. 2002, 303:695-703.
15. Comer S.D., Sullivan M.A., Walker E.A. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J. Pharmacol. Exp. Ther. 2005, 315:1320-1330.
16. Comer S.D., Sullivan M.A., Whittington R.A., Vosburg S.K., Kowalczyk W.J. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 2008, 33:1179-1191.
17. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol. Assess 2007, 11:1-171.
18. Daniulaityte R., Falck R., Carlson R.G. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Depend. 2011, 122:201-207.
19. Diaz-Gomez C., Obradovic I., Le Nezet O., Spilka S., Cadet-Tairou A., Mutatayi C. 2010 National Report to the EMCDDA 2010, Reitox National Focal Point, Paris.
20. Doerrbecker J., Behrendt P., Mateu-Gelabert P., Ciesek S., Riebesehl N., Wilhelm C., Steinmann J., Pietschmann T., Steinmann E. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J. Infect. Dis. 2013, 207:281-287.
21. Doran C.M., Shanahan M., Mattick R.P., Ali R., White J., Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003, 71:295-302.
22. EMCDDA Buprenorphine - treatment, misuse and prescription practices 2005, http://issues05.emcdda.europa.eu/en/page031-en.html.
23. EMCDDA The State of the Drugs Problem In Europe 2008, EMCDDA, Lisbon.
24. Gamkrelidze A., Javakhishvili J., Kariauli D., Lejava G., Stvilia K., Todadze K. Drug Situation in Georgia - 2003 2004, Southern Caucasus Anti-Drug Programme, Tbilisi, Georgia.
25. Gamkrelidze A., Javakhishvili J., Kariauli D., Lejava G., Stvilia K., Todadze K. Drug Situation in Georgia - 2004 2005, Southern Caucasus Anti-Drug Programme, Tbilisi, Georgia.
26. Hakansson A., Medvedeo A., Andersson M., Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur. Addict. Res. 2007, 13:207-215.
27. Javakhishvili D.J., Balanchivadze N., Kirtadze I., Sturua L., Otiashvili D., Zabransky T. Overview of the Drug Situation in Georgia, 2012 2012, Global Initiative on Psychiatry/Alternative Georgia, Tbilisi.
28. Javakhishvili D.J., Sturua L., Otiashvili D., Kirtadze I., Zabransky T. Overview of the drug situation in Georgia. Adictologie 2011, 11:42-51.
29. Javakhishvili J., Kariauli D., Lejava G., Stvilia K., Todadze K., Tsintsadze M. Drug Situation in Georgia - 2005 2006, Southern Caucasus Anti-Drug Programme, Tbilisi, Georgia.
30. Jenkinson R.A., Clark N.C., Fry C.L., Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction 2005, 100:197-205.
31. Johnson R.E., Strain E.C., Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003, 70(Suppl. 2):S59-S77.
32. Kirtadze I., Menon V., Beardsley K., Forsythe S. Assessing the Costs of Medication-Assisted Treatment for HIV Prevention in Georgia 2012, Futures Group USAID Health Policy Initiative Costing Task Order, Washington, DC.
33. Kruse G., Barbour R., Heimer R., Shaboltas A., Toussova O., Hoffman I., Kozlo A.P. Drug choice, spatial distribution, HIV risk, and HIV prevalence among injection drug users in St. Petersburg, Russia. Harm Reduct. J. 2009, 6:22.
34. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. The Fifth Edition of the Addiction Severity Index. J. Subst. Abuse Treat. 1992, 9:199-213.
35. Mravcik V., Pesek R., Horaková M., Necas V., Skarupova K., Stastna L. Annual Report: The Czech Republic-2009 Drug Situation 2010, Government of the Czech Republic, Prague.
36. O'Brien S., Black E., Degenhardt L., Roxburgh A., Campbell G., de Graaff B. Australian Drug Trends 2006 Findings from the Illicit Drug Reporting System (IDRS) 2006, National Drug Research Institute, Perth.
37. Otiashvili D., Srosi P., Somogyi G. Drug control in Georgia:drug testing and the reduction of drug use? The Beckley Foundation Drug Policy Program. Briefing Paper Oxford 2008, 15.
38. Otiashvili D., Zabransky T., Kirtadze I., Piralishvili G., Chavchanidze M., Miovsky M. Why do the clients of Georgian needle exchange programmes inject buprenorphine?. Eur. Addict. Res. 2010, 16:1-8.
39. Pickworth W.B., Johnson R.E., Holicky B.A., Cone E.J. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin. Pharmacol. Ther. 1993, 53:570-576.
40. Reckitt Benckiser Group US RB Pharmaceuticals Announcement 2012, Retrieved from http://www.rb.com/site/rkbr/templates/mediainvestorsgeneral2.aspx?pageid=1332andcc=gb (05.03.13).
41. Roux P., Villes V., Bry D., Spire B., Feroni I., Marcellin F., Carrieri M.P. Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addict. Behav. 2008, 33:1625-1629.
42. Simojoki K., Vorma H., Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst. Abuse Treat. Prev. Policy 2008, 3:16.
43. Singh J., Grover S., Basu D. Very high-dose intravenous buprenorphine dependence: a case report. Ger. J. Psychiatry 2004, 7:58-59.
44. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption 1992, Humana Press, Clifton, NJ. R. Litten, J. Allen (Eds.).
45. Sporer K.A. Buprenorphine: a primer for emergency physicians. Ann. Emerg. Med. 2004, 43:580-584.
46. Thibault V., Bara J.L., Nefau T., Duplessy-Garson C. Hepatitis C transmission in injection drug users: could swabs be the main culprit?. J. Infect. Dis. 2011, 204:1839-1842.
47. Tiihonen J., Krupitsky E., Verbitskaya E., Blokhina E., Mamontova O., Fohr J., Tuomola P., Kuoppasalmi K., Kiviniemi V., Zwartau E. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am. J. Psychiatry 2012, 169:531-536.
48. Uosukainen H., Kauhanen J., Voutilainen S., Fohr J., Paasolainen M., Tiihonen J., Laitinen K., Onyeka I.N., Bell J.S. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug Alcohol Depend. 2012, 127:207-214.
49. Verster A., Buning E. Buprenophine, Critical Questions Examined 2005, Euro-Methwork, Ireland.
50. Vicknasingam B., Mazlan M., Schottenfeld R.S., Chawarski M.C. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend. 2010, 111:44-49.
51. Winslow M., Ng W.L., Mythily S., Song G., Yiong H.C. Socio-demographic profile and help-seeking behaviour of buprenorphine abusers in Singapore. Ann. Acad. Med. Singapore 2006, 35:451-456.
52. Winstock A.R., Lea T., Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int. J. Drug Policy 2008, 19:450-458.
53. Zacny J.P., Conley K., Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J. Pharmacol. Exp. Ther. 1997, 282:1187-1197.